GLP-2 [HSA:9340] [KO:K04582] analog
Treatment of intestinal diseases characterized by chemical or surgical damage of the intestinal epithelium such as Short Bowel Syndrome (SBS) or damage to the intestinal epithelium due to disease
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16AX Various alimentary tract and metabolism products
A16AX08 Teduglutide
D06053 Teduglutide (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Gastrointestinal Agents
Gastrointestinal Agents, Other
Teduglutide
D06053 Teduglutide (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
24 Hormones
249 Miscellaneous
2499 Others
D06053 Teduglutide (USAN/INN); Teduglutide (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Secretin receptor family
Glucagon
GLP2R
D06053 Teduglutide (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06053
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D06053
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06053
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06053